Indivior PLC Cash Flow Conversion Efficiency
Indivior PLC cash flow conversion efficiency. Based on the latest financial reports, Indivior PLC (INDV) has a cash flow conversion efficiency ratio of -0.612x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (GBX158.00 Million ≈ $19.22K USD) by net assets (GBX-258.00 Million ≈ $-31.39K USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Indivior PLC (2011–2024)
Cash flow conversion efficiency of Indivior PLC from 2011 to 2024. This chart illustrates how Indivior PLC's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Indivior PLC share price for real-time trading data and today's change.
Indivior PLC Cash Flow Conversion Ratio Explained
Indivior PLC cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Indivior PLC Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Indivior PLC ranked by their cash flow conversion efficiency. Also see market cap of Indivior PLC for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Smithson Investment Trust PLC
LSE:SSON
|
0.000x |
|
Daesung Eltec Co. Ltd
KQ:025440
|
0.015x |
|
Lipidor Ab
ST:LIPI
|
-0.274x |
|
PERFORMANCE SHIPP.
F:DS2
|
0.030x |
|
Eureka Design Public Company Limited
BK:UREKA
|
0.002x |
|
Assura PLC
LSE:AGR
|
0.042x |
|
YoungWoo DSP Co.Ltd
KQ:143540
|
0.289x |
|
DC HEALTHCARE HOLDINGS BERHAD
KLSE:0283
|
0.134x |
Annual Cash Flow Conversion Efficiency for Indivior PLC (2011–2024)
The table below shows the annual cash flow conversion efficiency of Indivior PLC from 2011 to 2024. Review INDV free cash flow to operating cash ratio to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | GBX-348.00 Million ≈ $-42.34K |
GBX36.00 Million ≈ $4.38K |
-0.103x | -100.36% |
| 2023-12-31 | GBX-11.00 Million ≈ $-1.34K |
GBX-315.00 Million ≈ $-38.33K |
28.636x | +36611.36% |
| 2022-12-31 | GBX51.00 Million ≈ $6.21K |
GBX-4.00 Million ≈ $-486.68 |
-0.078x | -104.51% |
| 2021-12-31 | GBX203.00 Million ≈ $24.70K |
GBX353.00 Million ≈ $42.95K |
1.739x | +173.88% |
| 2020-12-31 | GBX82.00 Million ≈ $9.98K |
GBX-193.00 Million ≈ $-23.48K |
-2.354x | -425.77% |
| 2019-12-31 | GBX209.00 Million ≈ $25.43K |
GBX151.00 Million ≈ $18.37K |
0.722x | -84.26% |
| 2018-12-31 | GBX66.00 Million ≈ $8.03K |
GBX303.00 Million ≈ $36.87K |
4.591x | +415.92% |
| 2017-12-31 | GBX-203.00 Million ≈ $-24.70K |
GBX295.00 Million ≈ $35.89K |
-1.453x | -5.33% |
| 2016-12-31 | GBX-295.00 Million ≈ $-35.89K |
GBX407.00 Million ≈ $49.52K |
-1.380x | -20.29% |
| 2015-12-31 | GBX-279.00 Million ≈ $-33.95K |
GBX320.00 Million ≈ $38.93K |
-1.147x | -23.82% |
| 2014-12-31 | GBX-475.00 Million ≈ $-57.79K |
GBX440.00 Million ≈ $53.54K |
-0.926x | +92.27% |
| 2013-12-31 | GBX-66.00 Million ≈ $-8.03K |
GBX791.00 Million ≈ $96.24K |
-11.985x | -300.67% |
| 2012-12-31 | GBX145.00 Million ≈ $17.64K |
GBX866.00 Million ≈ $105.37K |
5.972x | +112.17% |
| 2011-12-31 | GBX254.00 Million ≈ $30.90K |
GBX715.00 Million ≈ $86.99K |
2.815x | -- |
About Indivior PLC
Indivior PLC, together with its subsidiaries, develops, manufactures, and sells buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in the United States, Europe, Canada, Australia, and internationally. The company develops medicines to treat substance use disorders. Its core marketed products include SUBLOCADE buprenorphine extended-release monthly … Read more